International Society for Heart and Lung Transplantation

About Us

The International Society for Heart and Lung Transplantation is a multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy. The International Society for Heart and Lung Transplantation was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2500 members from over 45 countries, representing over 14 different disciplines involved in the management and treatment of end-state heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Quotes

The GRIPHON study is indeed a groundbreaking step forward in pulmonary hypertension. ISHLT has a profound interest in these results as pulmonary hypertension is one of the key areas the society is concentrating on in the future.

Andreas Zuckermann, MD, ISHLT 2015 Scientific Program Committee Chair

LVADs continue to prove to be a viable treatment option for patients with heart failure. The ROADMAP trial is important to ISHLT as LVAD research and therapy continue to show positive results

Andreas Zuckermann, MD, ISHLT 2015 Scientific Program Committee Chair

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

NEW PARADIGMS FOR ORGAN PRESERVATION IN HEART AND LUNG TRANSPLANTATION

Sat, Apr 18, 2015 11:30 CET

NICE, FR (April, 18, 2015) – During the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting and Scientific Sessions , April 15-18 in Nice, France, several abstracts were presented calling attention to the novel approaches in heart and lung organ preservation including the supercooling of organs for transplant. The study found that keeping an organ at below-freezing temperatures could extend preservation time by further slowing metabolism. The study, conducted on rat livers, found that supercooling of the organ can more than triple the

LONGTERM, MULTICENTER, MULTINATIONAL DATA IN PULMONARY ARTERIAL HYPERTENSION PRESENTED AT ISHLT MEETING

Sat, Apr 18, 2015 10:40 CET

NICE, FR April, 18, 2015 – Today at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions , researchers presented long-term results from The GRIPHON trial demonstrating that selexipag (Uptravi®) is an effective treatment therapy for pulmonary arterial hypertension (PAH). The trial, a multicenter,

UPDATED HEART AND LUNG CONSENSUS REPORTS PRESENTED AT INTERNATIONAL SOCIETY OF HEART AND LUNG TRANPLANTATION ANNUAL MEETING

Sat, Apr 18, 2015 10:40 CET

NICE, FR (April, 18, 2015) – During the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting and Scientific Sessions , April 15-18 in Nice, France, working groups presented consenus reports in Antibody mediated rejection (AMR) in Lung Transplantation and updates to listing criteria in heart transplantation (Tx). Mandeep R. Mehra, MD, Medical Director, Brigham and Women’s Hospital Heart and Vascular Center And Professor of Medicine, Harvard Medical School presented an update to ISHLT’s listing criteria for heart transplantation candidates,

ROADMAP STUDY DEMONSTRATING BENEFITS OF HEARTMATE II® LEFT VENTRICULAR ASSIST DEVICE PRESENTED AT ISHLT CONFERENCE

Fri, Apr 17, 2015 09:10 CET

NICE, FR April, 17, 2015 – Today at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions , researchers presented one-year results from the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). The study evaluated the effects of Thoratec Corporation’s (NASDAQ: THOR) HeartMate II® Left Ventricular Assist Device (LVAD) compared with optimal medical management patients. Results from the

Multicenter ENDURANCE Trial of Patients with Advanced Heart Failure Presented at ISHLT Meeting

Fri, Apr 17, 2015 08:30 CET

NICE, FR (April, 17, 2015) – Yesterday, results of the ENDURANCE destination therapy clinical trail were presented at the 35th Annual International Society for Heart and Lung Transplantation Meeting and Scientific Sessions , by Francis D. Pagani, M.D., Ph.D., University of Michigan, a co-principal investigator for ENDURANCE. Results showed no significant difference in overall patient survival, confirming non-inferiority was established for the HeartWare® assist device compared with the control device for destination therapy in patients with end-stage heart failure.

There are no items matching the current filter

There are no more items matching the current filter

Share